Clinical Scorecard: The Relationship Between Shunt Dependency and Tumor Resection Extent in Supratentorial Intraventricular Tumors

At a Glance

Key Highlights

• SIVTs are rare, comprising 1–3% of intracranial lesions, with diverse histological entities arising primarily or secondarily within the ventricular system.
• Surgical management aims for maximal safe tumor resection via various approaches tailored to tumor location, balancing tumor removal and preservation of eloquent brain structures.
• Multiple shunting strategies exist to manage obstructive hydrocephalus perioperatively, including external ventricular drainage, ventriculoperitoneal/atrial shunts, endoscopic third ventriculostomy, and stereotactic internal shunting.

Guideline-Based Recommendations

Diagnosis

• Use MRI with contrast-enhanced T1-weighted and FLAIR/T2 sequences for tumor volume assessment and hydrocephalus evaluation.
• Diagnose occlusive hydrocephalus radiologically by ventricular enlargement and transependymal CSF diapedesis.
• Histopathological diagnosis should follow the 2021 WHO CNS tumor classification based on tissue obtained via microsurgical resection or biopsy.

Management

• First-line therapy for symptomatic SIVTs is complete microsurgical or neuroendoscopic tumor resection.
• Adjuvant therapy is considered depending on histological tumor entity.
• Benign cystic lesions (e.g., colloid or pineal cysts) may be managed with minimally invasive stereotactic procedures.
• Shunting strategies for hydrocephalus include perioperative external ventricular drainage, ventriculoperitoneal or atrial shunts, endoscopic third ventriculostomy, and stereotactic internal shunting.
• Choice of shunting procedure should be individualized; the necessity of shunting after complete tumor removal remains unclear.

Monitoring & Follow-up

• Follow-up imaging per institutional guidelines based on tumor type and clinical status.
• Surveillance MRI to assess for residual tumor and hydrocephalus.
• Monitor for new or worsening neurological deficits postoperatively.

Risks

• Surgical risks include injury to eloquent deep brain and neurovascular structures.
• Postoperative neurological deficits may range from mild to severe, including seizures, cranial nerve deficits, aphasia, motor/sensory impairments, and cognitive decline.
• Hydrocephalus persistence may require additional shunting procedures.

Patient & Prescribing Data

Patients undergoing microsurgical or neuroendoscopic resection for supratentorial intraventricular tumors with or without hydrocephalus

Extent of tumor resection and choice of shunting strategy influence postoperative hydrocephalus management; individualized treatment plans are essential.

Clinical Best Practices

• Perform maximal safe tumor resection tailored to tumor location within the ventricular system to minimize brain retraction and preserve critical structures.
• Use volumetric MRI analysis to define extent of resection and residual tumor burden.
• Assess and manage hydrocephalus perioperatively with appropriate shunting techniques based on clinical and imaging findings.
• Engage interdisciplinary brain tumor boards for diagnostic and therapeutic decision-making.
• Classify postoperative neurological deficits by severity to guide management and rehabilitation.

References

• World Health Organization Classification of CNS Tumors 2021
• RANO Criteria for Brain Tumor Imaging
• BrainLab Elements Imaging Software